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Abstract
Background: The ShockOmics study (ClinicalTrials.gov identifier NCT02141607) is a multicenter prospective
observational trial aimed at identifying new biomarkers of acute heart failure in circulatory shock, by means of a
multiscale analysis of blood samples and hemodynamic data from subjects with circulatory shock.
Methods and Design: Ninety septic shock and cardiogenic shock patients will be recruited in three intensive care
units (ICU) (Hôpital Erasme, Université Libre de Bruxelles, Belgium; Hospital Universitari Mutua Terrassa, Spain;
Hôpitaux Universitaires de Genève, Switzerland). Hemodynamic signals will be recorded every day for up to seven
days from shock diagnosis (time T0). Clinical data and blood samples will be collected for analysis at: i) T1 < 16 h
from T0; ii) T2 = 48 h after T0; iii) T3 = day 7 or before discharge or before discontinuation of therapy in case of fatal
outcome; iv) T4 = day 100.
The inclusion criteria are: shock, Sequential Organ Failure Assessment (SOFA) score > 5 and lactate levels≥ 2 mmol/L.
The exclusion criteria are: expected death within 24 h since ICU admission; > 4 units of red blood cells or >1 fresh
frozen plasma transfused; active hematological malignancy; metastatic cancer; chronic immunodepression; pre-existing
end stage renal disease requiring renal replacement therapy; recent cardiac surgery; Child-Pugh C cirrhosis; terminal
illness. Enrollment will be preceded by the signature of the Informed Consent by the patient or his/her relatives and by
the physician in charge.
Three non-shock control groups will be included in the study: a) healthy blood donors (n = 5); b) septic
patients (n = 10); c) acute myocardial infarction or patients with prolonged acute arrhythmia (n = 10).
The hemodynamic data will be downloaded from the ICU monitors by means of dedicated software. The
blood samples will be utilized for transcriptomics, proteomics and metabolomics (“-omics”) analyses.
Discussion: ShockOmics will provide new insights into the pathophysiological mechanisms underlying shock
as well as new biomarkers for the timely diagnosis of cardiac dysfunction in shock and quantitative indices
for assisting the therapeutic management of shock patients.
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Background
The clinical protocol “ShockOmics: Multiscale Approach
to the Identification of Molecular Biomakers in Acute
Heart Failure Induced by Shock”, (ClinicalTrials.gov
identifier NCT02141607) is part of a complex project
which combines the observational clinical study de-
scribed in this manuscript with animal research and
in vitro experiments to investigate the fundamental
mechanisms of acute heart failure (AHF) in circulatory
shock. The goals of the project are the identification of
novel biomarkers of shock-induced AHF, the formula-
tion of a multiscale approach to the diagnosis and in-
terpretation of the disease, and the design of new
technologies and therapeutic strategies for improving
the delivery of care in shock patients.
Circulatory shock is a life-threatening clinical condi-
tion, characterized by low tissue perfusion and ensuing
cellular damage and organ dysfunction, which affects
about one third of patients admitted to the intensive
care unit (ICU) [1], with very high mortality rates. Four
types of shock are commonly defined according to
their hemodynamic patterns: hypovolemic shock (e.g.,
hemorrhagic shock (HS)), cardiogenic shock (CS), dis-
tributive shock (e.g., septic shock (SS)), and obstruct-
ive shock [1, 2].
Septic shock is the most common form of shock,
which can occur as a complication of sepsis caused by
infection. Sepsis and ensuing shock are the leading cause
of mortality in the ICU, among the top 15 leading causes
of death overall, with a reported mortality rate above
40 %, and more than 200,000 deaths per year in the
United States only [3–9]. Recent trials have reported
lower mortality rates around 30 % [10–12].
Cardiogenic shock is the second most frequent form
of shock, caused by sudden heart failure, due for in-
stance to a severe heart attack. Novel technologies (e.g.
extracorporeal membrane oxygenation (ECMO)) have
contributed to a reduction of the mortality of cardio-
genic shock below 50 % [13–15], but its lethality remains
extremely high.
Hemorrhagic shock is a form of hypovolemic shock
due to blood loss. It occurs in 36–39 % of the victims of
trauma resulting from accidental injuries, which is the
leading cause of death at the age between 1 and 44 in
the U.S.A. [16, 17].
A frequent consequence of circulatory shock is the de-
velopment of multiple organ failure (MOF), a condition
in which organs not directly affected by the original in-
sult become dysfunctional and eventually contribute to
poor outcome. In the specific case of the heart, its func-
tion can be directly impaired by cardiac disease, such as
acute myocardial infarction or prolonged arrhythmias,
which causes cardiogenic shock and low cardiac output.
However, in the other forms of shock, the heart can fail
in the general context of MOF [18, 19]. Although the
goal of restoring an adequate level of perfusion is to pre-
vent any organ from failing, the protection of the heart
and the preservation of its function are instrumental for
ensuring hemodynamic stability, and an adequate perfu-
sion of all vital organs.
The relationship between shock, hypotension and
hemodynamic instability, inflammation and MOF has been
extensively investigated, but the mechanisms that ultim-
ately trigger molecular and cellular injury which cause tis-
sue and organ dysfunction remain largely undetermined,
so that there is no clear therapeutic target. Hence, current
therapies are targeted to restoration of hemodynamic vari-
ables and reduction of symptoms of shock/MOF, but they
are unable to act at the “beginning of the cascade”.
Vital signs available from measurements or estimates in
critical care settings, such as electrocardiogram (ECG), ar-
terial blood pressure (ABP), central venous pressure
(CVP), stroke volume (SV) and cardiac output (CO), pul-
monary artery pressure (PAP), pulmonary capillary oc-
cluded pressure (PAOP), and photo-plethysmographic
(PPG) pulse-oximetry are routinely used for monitoring
purposes. They convey instantaneous information on the
CV status of the patient, but they cannot accurately pre-
dict the occurrence of hypotensive episodes and are often
not sufficient to guide a timely and effective Early Goal
Directed Therapy [20–22], because of the poor under-
standing of the pathological cascades characterizing shock
[23–34]. As a consequence, the success of any interven-
tion, such as fluid resuscitation, vasopressor therapy and
the use of inotropes is limited and depends on the
trade-off between their short-term beneficial effect
and their potential long-term risk. Fluids may restore
blood pressure within minutes, but serious complications
such as pulmonary edema may arise thereafter as a conse-
quence of excessive fluid administration, causing alter-
ations in tissue perfusion, delay in organ recovery and
prolonged supportive therapies, such as mechanical venti-
lation. Vasoactive drugs are used to maintain blood
pressure but present the risk of increasing the cardiac
afterload and/or facilitating the occurrence of arrhythmias.
Hence, their use can further stress the heart, potentially
hampering its residual functionality [32–34].
In the context of low blood pressure, low flow, and re-
duced ventricular contractility typical of circulatory
shock and hemodynamic instability, careful monitoring
of heart function is essential to prevent further tissue hy-
poperfusion and subsequent organ failure. ShockOmics
focuses on acute heart failure due to shock, and will ex-
plore the presence of biomarkers, which could be related
(but not limited) to a cascade of pathogenic phenomena,
whose onset is potentially associated to the role of the
intestine and of the endocrine glands as a source of
powerful mediators for tissue injury [26, 35]. ShockOmics
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aims at investigating the molecular triggers of AHF asso-
ciated with shock and to identify inflammatory media-
tors and markers which are activated after an initial
insult, with a particular emphasis on the role of uncon-
trolled proteolytic activity as a major cause of severe tis-
sue injury. To achieve this goal, a systematic analysis of
expression levels of transcripts, genes and their protein
products, and of peptides generated by proteolysis will
be carried out on blood samples obtained from ICU pa-
tients hospitalized. Based on the preliminary identifica-
tion of candidate biomarkers of shock-induced AHF,
animal experiments and in vitro studies will further
validate the initial hypotheses on the fundamental mech-
anisms and on the biomarkers of the disease. This ap-
proach, besides focusing on new biomarkers of the
disease, will aim to define new targets for therapy, in
order to overcome the shortcomings of current therapies
for circulatory shock. The final outcome of ShockOmics
will be a multiscale integration of the information from
different scales of investigation, from gene expression, to
protein synthesis and metabolite expression, to organ
specific injury in the heart and hemodynamic patterns
characterizing the alteration of CV function in shock. In
this framework, an important aspect is the interpretation
of the patho-physiological changes in system level vari-
ables, i.e. CV measurements, which are routinely available
in emergency departments, ICUs and operating rooms, in
function of the fundamental processes of disease.
The objectives of the clinical study included in the
framework of the ShockOmics project will specifically ad-
dress the following questions:
a) What are the circulating biomarkers of AHF and
subsequent hemodynamic instability?
b) What is the relationship between such biomarkers,
the biochemical parameters, and the hemodynamic
measurements, which are routinely available in the
ICU?
c) What are the regulatory points in the cascade,
which could become targets for a cardioprotective
therapy against shock?
The expected outcomes of the clinical study will be:
1) Definition of candidate biomarkers by means of
cutting edge –omics techniques;
2) Development of an innovative multiscale, systems
biology based models to describe the relationship
between hemodynamic measurements/waveforms
available in ICU/OR/ED and the progression of
shock induced AHF;
3) Identification of novel targets for effective
cardioprotective therapies to prevent/contrast
shock progression;
4) Creation of a complex and detailed database of
hemodynamic signals collected from the ICU
monitors.
Methods and design
The ShockOmics clinical protocol defines the specifics of
a multicenter prospective observational study meant to
evaluate molecular mechanisms underlying shock and
associated with AHF.
The ICUs involved in the clinical study are located in
the following hospitals:
 Hôpitaux Universitaires de Genève, Université de
Genève (Geneva, Switzerland)
 Hôpital Erasme, Université Libre de Bruxelles
(Brussels, Belgium)
 Hospital Mutua de Terrassa (Terrassa, Spain)
All Institutional Ethical Committees in the three par-
ticipating institutions approved the clinical protocol.
ShockOmics will recruit severe SS and CS patients. Se-
vere HS patients will be also recruited, but their inclu-
sion in the study will be limited to the system level
investigation of the features of the hemodynamic signals,
while the –omics analyses will not be carried out for this
group (see Discussion section).
The study will recruit 90 patients suited for analysis
with full data collection available, i.e., well preserved
blood samples, high quality hemodynamic recordings, all
clinical, anamnestic, diagnostic and prognostic data. The
patients will be classified according to existing shock
severity scores, such as the Sequential Organ Failure
Assessment (SOFA) score and the Acute Physiology And
Chronic Health Evaluation (APACHE) II [36]. In par-
ticular, the SOFA score will be utilized to set the thresh-
old of shock severity as one of the inclusion criteria of
the study (see Inclusion and Exclusion Criteria).
Sample size
The sample size was computed taking into consideration
the following assumptions:
1. ShockOmics is an exploratory observational study
aimed at testing new hypotheses on the molecular
mechanisms of shock and consequent secondary
organ failure, particularly AHF. Such hypotheses will
be further explored and validated in animal models.
2. Incidence of AHF in the population is low (average
estimate 1.3 cases/1,000 subjects, increasing with age
up to 11.6/1,000 in those aged 85 years and over)
[37, 38]. Conversely, MOF and specifically AHF are
a frequent and often lethal complication in shock
patients. Shock increases re-hospitalization rates,
organ failure and associated mortality even after ICU
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discharge [39]. Therefore, we expect to observe the
activation of inflammatory factors and pathogens
because of the local and systemic ischemia/reperfusion
episodes occurring in shock, with an increased risk of
AHF.
3. Based on experimental and preclinical studies, we
expect to test the occurrence of uncontrolled
proteolytic activity, caused by serine proteases,
metalloproteinases and other enzymes.
The sample size of n = 90 patients was calculated con-
sidering as outcome a quantitative measurement of car-
diac function (i.e. cardiac output), and the following
parameters: a) an Effect Size (f2) of 0.205 (for a strength
of association equal to R2 0.17); b) α type I error prob-
ability equal to 0.05; c) power = 81 %, using a multiple
linear regression; d) 10 predictors tested in the model
and giving the effect size.
If the strength of association (R2) for the selected set
of predictors is equal to 0.20, the Effect Size (f2) would
increase to 0.25, giving to the study a Power of 89 %,
while for models with R2 higher than 0.24 the Power ob-
tained would be higher than 95 %.
The analyses of the blood samples and hemodynamic
measurements will entail both analyses of the total
sample (n = 90), which will allow the identification of
common predictors across different types of shock,
and of the subgroups of the different types of shock,
which will allow to identify specificities associated to
the disease etiology. A minimum sample size of n = 30 pa-
tients is needed per each subgroup in order to identify
a set of predictors producing an Effect Size equal to
0.43 (for a strength of association equal to R2 0.30),
testing up to 3 predictors, with a Power of 80 %, and
type I error α equal to 0.05. A maximum sample size
of n = 60 patients will enable to identify a set of pre-
dictors producing an Effect Size equal to 0.25 (for a
strength of association equal to R2 0.20), testing up
to 6 predictors with a Power of 80 %, and type I
error α equal to 0.05.
In the specific case of hemorrhagic shock not deter-
mined by pre-existing pathologies (e.g., trauma patients),
we expect the risk factors of low perfusion (i.e., reduced
cardiac output) in these patients to be strictly related to
shock. HS patients will be considered as reference shock
population.
We will use data from septic patients and patients
with acute heart disease not in shock together with
septic shock and cardiogenic shock patients to con-
duct logistic regression analysis. Each subgroup ana-
lysis will be run on minimum of 40 subjects, allowing
to identify single predictors with an Odds Ratio of 2.85 on
a binary response variable defined as “shock onset”, with a
Power of 83 % and type I error α equal to 0.05.
The sample size was estimated using G*Power 3
Calculator. We estimate that each ICU will recruit n = 50
patients in order to reach the above mentioned sample
size, considering a drop out rate of ~40 %.
Patient groups
Septic shock (n = 60)
Septic shock is defined as sepsis-induced hypotension,
characterized by systolic blood pressure < 90 mmHg or a
drop of > 40 mmHg from baseline or mean arterial
pressure < 65 mmHg, persisting despite adequate fluid
resuscitation. Adequate resuscitation will be consid-
ered achieved when a volume of at least 30 ml/kg of
crystalloids will be administered. Additional fluid re-
suscitation will be guided using hemodynamic moni-
toring according to local practices. Subgroup analyses
will be undertaken to compare the community-acquired
and nosocomial-acquired infections.
Cardiogenic shock (n = 30)
Cardiogenic shock is defined as a state of inadequate
circulation of blood because of ventricular failure due to
acute cardiac conditions, such as acute myocardial
infarction (AMI) or prolonged arrhythmias (PA).
Additionally, characteristics of the CS patients re-
cruited in ShockOmics will be: hypotension, charac-
terized by systolic blood pressure < 90 mmHg or a
drop of > 40 mmHg from baseline or mean arterial
pressure < 70 mmHg, persisting despite adequate
fluid resuscitation; Cardiac Index <1.8 L/min/m2 without
supports or < 2.0–2.2 L/min/m2 with the support of ino-
tropic drugs (e.g. dobutamine/isoprenaline/phospho-
diesterase inhibitors or levosimendan) or of cardiac
assistance devices; cardiac overload or altered left/
right ventricular function are assessed by typical
echocardiographic indices [15]:
 Left ventricular (LV) volume and ejection fraction
(EF) estimated by the apical biplane method of disks
(modified Simpson’s rule):
– EF <35 % = systolic heart failure
– LV diastolic volume/ body surface area (BSA) >
97 ml/m2 = severe LV dilation
 Aortic velocity time integral (VTI) measured by PW
Doppler on LVOT:
– Abnormal if < 18 cm
– Severely abnormal if < 14 cm
 Mitral annular diastolic PW tissular Doppler
velocities:
– Lateral E/E’ >12 = high LV filing pressure
– E/E’ <8 = normal LV filing pressure
 Right ventricular /left ventricular (RV/LV) diameter
(or cross section area) ratio > 1 = severe RV overload
(intermediate if between 0,6 and 1).
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 Paradoxical inter-ventricular septum motion
(or “D-shape”) = severe RV overload
Hemorrhagic shock (n = 15)
Hemorrhagic shock is a hypovolemic form of shock,
characterized by the rapid loss of significant
amounts of blood, systolic blood pressure < 90 mmHg
or a drop of > 40 mmHg from baseline or mean ar-
terial pressure < 65 mmHg. The HS patients enrolled
in the study will be analyzed exclusively from the
standpoint of their hemodynamic records and clin-
ical data.
Control groups (n = 30)
The ShockOmics study will also entail the collection of
blood samples and hemodynamic data when possible in
comparison groups of healthy subjects or patients not it
shock:
 n = 5 healthy blood donors will be collected for the
purposes of obtaining reference values for
proteomics analysis
 n = 10 septic patients not in shock: sepsis caused by
infections with inflammatory response with one
organ dysfunction at most (as indicated by SOFA
sub-scores for specific organ function), without
organ support therapy (i.e., mechanical ventilation,
renal replacement therapy) and with lactate
levels < 2 mmol/L
 n = 10 cardiac patient not in shock, affected by AMI
or PA patients
Inclusion and exclusion criteria
The inclusion criteria of ShockOmics are:
 SOFA score > 5
 First blood sample and first hemodynamic
measurements available within 16 h from admission
to the ICU
 Informed Consent available: the consent will be
requested to the patient, or to its relatives in case of
altered consciousness, and signed by the physicians
responsible for ShockOmics in the ICU. Delayed
consent may be asked according to local rules and
regulations in case the relatives were unavailable at
the time of potential enrollment
The exclusion criteria of ShockOmics are:
 Risk of fatal illness and death within 24 h
 Patients already enrolled in other interventional
studies
 More than 4 units of red blood cells transfused
 Patients receiving plasma or whole blood
 Active hematological malignancy
 Metastatic and/or active cancer
 Immunodepression, including transplant patients;
patients infected by the human immunodeficiency
virus (HIV+); constitutive immune system deficiency;
any immunosuppressive therapy, including oral and
parenteral corticosteroids (aerosols are allowed)
 Patients with pre-existing end stage renal disease
needing renal replacement therapy. The introduction
of continuous veno-venous hemofiltration from the
day of admission onward is allowed
 Cardiac surgery in the previous ten days
 Child-Pugh C cirrhosis or acute liver failure
 Terminal illness
Timeline of data collection
– Time 0 (T0): admission to the ICU with diagnosis of
shock or time of shock diagnosis in patients initially
admitted without shock symptoms (see inclusion/
exclusion criteria above);
– Time 1 (T1): time at which the first blood sample for
analysis is collected, within 16 h after T0. This time
point is considered representative of acute shock
before the therapy has taken effect, when shock has
already activated the main patho-physiological
cascades of inflammation and disease;
– Time 2 (T2): time at which the first blood sample
for analysis is collected, at 48 h after T0. At this
time point, the treatment has been administered for
a long enough amount of time to evaluate its effects
on the early molecular markers of disease;
– Time 3 (T3): time at which the third blood sample for
analysis is collected, on day 7 of the ICU stay of the
patient or before discharge from the ICU in case of
shorter stays or before discontinuing therapy (death).
At this time point, the activated molecular pathways
and the relevant system level consequences are
assumed to have reached a steady state condition;
– Time 4 (T4): follow up (FU) on ~ day 100 from Time
0. A blood sample will be collected in survivors who
will not be re-hospitalized for the consequences of
shock during the time between T3 and T4.
The time course of data collection for the protocol is
shown in Fig. 1.
Clinical endpoints
The clinical endpoints that will be used to evaluate
shock progression are:
 AHF assessed by a pool of measurements/estimates of
cardiac function, including cardiac output, filling
pressures, inotropic drugs requirements, left and right
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ventricles function estimated by echocardiography.
AHF will be at evaluated at Time 1, 2, 3
 Mechanical ventilation free days or organ
support -days
 ICU survival
 Outcome at discharge from the ICU (objective: dead
or alive, morbidities; subjective)
 Outcome at discharge from the hospital (objective:
dead or alive, morbidities; subjective)
Clinical data collection
The following anamnestic and clinical data will be re-
corded daily from T1 until T3:
 Laboratory data from urine and blood samples
 Comorbidities
 Severity scores (SOFA and APACHE II scores)
 Time from onset of symptoms to shock diagnosis
 Time from ICU/ER admission to shock diagnosis
 Biochemical parameters, e.g. lactate levels, pH, etc.
 Therapy (drugs, fluids, etc.), temperature, urine
output, stool production, bowel sound, abdominal
fullness, appetite, food and fluid consumption or
fasting, nausea and vomiting
 Cardiorespiratory assistance (mechanical ventilation,
ECMO, intra-aortic balloon pump, etc.)
 Assessment of organ failure, and in particular heart
failure
 Cognitive assessment (encephalopathy) - by SAS,
RASS and CAM-ICU scale
 For the patients not discharged from the ICU on day 7,
the clinical data will be recorded on day: 10/15/22/30
and every 15 days until discharge from the ICU
Biological samples
Urine and blood samples will be collected at the times
T1, T2, and T3. The typical management of shock
patients in ICU requires arterial, venous and urinary
catheterization. These accesses are routinely used for
drug/fluid administration and will also be used for the
collection of the samples for analysis.
The ICU staff will contact survivors in order to
schedule a follow-up visit on day 100 (T4, Recovery),
during which a blood sample will be withdrawn for
analysis.
The collection and analysis of urine will permit to
evaluate standard biochemical parameters, routinely re-
quired to integrate the information from blood analysis,
such as for instance kidney function, liver function, me-
dullary function, etc.
Hemodynamic monitoring
The hemodynamic data will be downloaded from the
bedside ICU monitor on a laptop computer by means of
dedicated software. Details on the implementation of the
solutions to the technical issues of downloading signals
from the monitors and on the acquisition protocol are
addressed in the Discussion section.
The continuous waveforms, which will be routinely
accessible, include:
– ECG
– ABP, via an arterial catheter inserted in the femoral
or radial artery
– CVP, in patients with a central venous line with a
pressure transducer
– PPG
– Respiratory signals: bio-impedance or thoracic belt
– Continuous SpO2
Further, continuous and non-continuous measurements
and estimates, which will be available intermittently, will
include:
Fig. 1 Time course of the monitoring of a patient enrolled in the ShockOmics study (hemodynamic data acquisition and blood samples). The
hemodynamic data are collected daily during the observation window (up from time 0 on day 1 up to day 7). The total number of blood
samples is 3: the first sample is collected at T1, the second at T2, and the third at T3, which can occur on any day between day 4 and day 7
(T3 occurring on day 7 in case of ICU stay longer than 7 days or on day 4–6 in case of early discharge or death)
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 Continuous measurements of PAP, PAOP, and
estimates of CO via thermodilution, by means of a
pulmonary artery catheter, when in use
 Stroke volume, CO, global end diastolic volume,
extravascular lung water from trans-pulmonary ther-
modilution (PiCCO ® [Pulsion Medical System])
when in use
 Trans-thoracic or trans-oesophageal echocardio-
graphic assessment on admission, on Day1, Day2,
Day3, Day7/Discharge/Death
 Ventilation parameters (settings of mechanical
ventilation if applicable; including pressure, tidal
volume, static compliance, etc.) on Day1, Day2,
Day3, Day7/Discharge/Death
 Central or mixed venous oxygen saturation and
artero-venous pCO2 difference on Day1, Day3,
Day7/Discharge/Death.
Protocol documentation
Each Experimental Center will archive the patient
documentation in a Trial Centre File, which will
include:
 Study Protocol signed by all relevant individuals
 European Commission Approval Notification
 Administrative Approval Notification (from the
hospital)
 Any relevant correspondence/contracts between
Funding agency (EU) and the ShockOmics
consortium
 Completed transcoding file: including the
transcoding from anonymized study codes and
patient name, last name, date of birth, etc.
 Informed Consent and Privacy
 Individual data of the patient, i.e. Case Report
Form (CRF) and hemodynamic tracings, dated
and signed by the Investigator in charge for the
center
 Safety Session: including all documentation related
to severe adverse events incurred during the
hospitalization
Discussion
In this section, we discuss the solutions that were de-
vised to address the main technical issues faced dur-
ing the set-up stage of the clinical protocol, such as:
high fidelity hemodynamic waveform download from
the bedside monitor and storage in a database; guide-
lines for the treatment of blood samples to be used
for –omics analyses; the definition of control groups;
the inclusion in the study of a hemorrhagic shock
group and the relevant limitations; the timeline of the
project.
Software for the download of the hemodynamic signals
from the monitors, CRF and database
The three ICUs participating in ShockOmics are equipped
with different bedside monitors:
– Hôpitaux Universitaires de Genève: Philips Intellivue
MP70 ® (version K)
– Hôpital Erasme, Université Libre de Bruxelles:
Dräger INFINITY (C700 +M540 ®)
– Hospital Mutua de Terrassa: Philips Intellivue MP70
® (2012 Software)
A laptop computer will be connected to the monitor
and hemodynamic and ventilation signals will be syn-
chronously downloaded by means of dedicated software
programs.
The following software will be used:
– Hôpitaux Universitaires de Genève: ixTrend
Professional 2.0 ® (ixellence GmbH, Wildau,
Germany)
– Hôpital Erasme, Université Libre de Bruxelles:
NOTOCORD-hem Evolution ® (NOTOCORD
Systems SAS, France)
– Hospital Mutua de Terrassa: Better Care software ®
(Better Care S.L., Sabadell, Spain).
The signals, which will be typically downloaded from
the monitors and stored in the database, include:
– Electrocardiogram at a sampling frequency,
fs = 500Hz, 200Hz, 1000Hz
– Central arterial blood pressure, fs = 125 Hz, 200Hz
– Central venous pressure when a central venous line
is present, fs = 200 Hz
– Pulse oximeter photoplethysmography signals,
fs = 200Hz, 125Hz
– Respiratory signals: bioimpedance, fs = 62.5 Hz;
thoracic belt, fs = 100Hz, 200Hz.
The different sampling rates are due to the different
monitors and acquisition systems.
Prior to the implementation of the software-monitor
interface, pilot tests on signals collected by the different
software programs were run to verify the reliability of
the acquisition procedures and the quality of the signals
for the computation of the derived variables (e.g. systolic
blood pressure series) which are required for the subse-
quent mathematical analysis. The exportation of data in
the same format (e.g., as .csv files) ensures that there is
no difference in the treatment of the signals by the soft-
ware that could potentially hamper the consistency of
the analysis, independent of the interface implemented
to record the data, and also of the ICU monitor.
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The signals will be uploaded in the patient CRF, which
is stored in the ShockOmics database. The CRF and the
database architecture were developed by the ShockOmics
partner Custom Software & Electronics, SL, Barcelona,
Spain. The CRF is a multi-field electronic file in which
the clinical data and hemodynamic signals collected
during the ICU stay of a patient enrolled in the protocol
are stored.
An appropriate signal collection protocol was de-
signed, in order to generate a uniform hemodynamic
database, and to optimize the workload of the physicians
in the ICUs. Typical recordings will take place after rou-
tine patient washing. ECG, hemodynamic, and respira-
tory signals will be downloaded to the laptop and real
time annotations will be carefully taken during standard
maneuvers to test the hemodynamic status of the pa-
tients, such as end expiratory occlusion test in deeply se-
dated patients, fluid challenge, vasopressor challenge,
etc. Besides the inclusion of specific maneuvers in the
hemodynamic recordings, longer recordings without the
presence of specific maneuvers may be collected in order
to evaluate the long-term dynamics in the cardiovascular
signals.
The hemodynamic signals will be analyzed by
means of advanced mathematical techniques in order
to derive clinically relevant information from the
available waveforms (e.g. cardiac output estimates,
stroke volume and pulse pressure variation in cor-
respondence of fluid challenges, cardiovascular vari-
ability indices such as baroreflex sensitivity, non
linear indices of heart rate and blood pressure dy-
namics, etc.).
The recordings will be collected every day during the
window of observation defined in the protocol (see
above, 7 days in case of early discharge from the ICU or
death).
The database of ShockOmics will include all the
CRFs of the patients enrolled in the study and all the
cardiovascular signals downloaded from the ICU
monitors. Further, an appropriate storage space has
been foreseen for the most important parameters of
the –omics analyses, which will be performed on the
blood samples withdrawn from the patients at T1, T2,
T3, and T4 when possible. The database will be par-
tially available to researchers who will apply to access
it for analysis of the data, following the expression of
interest in a collaboration with the ShockOmics
consortium and a request of access to the database
which will be evaluated internally by ShockOmics
consortium. Partial access to the database (e.g., the
hemodynamic recordings) will be made freely avail-
able to the scientific community upon completion of
the clinical study and of the analyses to be performed
by the ShockOmics consortium.
Blood sample handling and pre-processing for –omics
analysis
Each of the blood samples (at T1, T2, T3, T4 for the
survivors) collected for the –omics analysis will be
studied by means of transcriptomics, proteomics, and
metabolomics analyses.
A volume equal to 10 mL of blood will be withdrawn
at the 4 points in time indicated above, according to the
following protocol:
 1 mL of peripheral venous blood will be withdrawn
in Ethylen Diamine Tetra-Acetate (EDTA)
 Subsequently, two aliquots of 0,5 mL of blood will
be distributed in two vials containing 0,5 mL of
stabilizing reagent, then gently mixed and stored
at -20 °C
 Plasma (for transcriptomic studies): 6 mL of
blood in EDTA-coated tube, centrifuged at 1300 g
for 10 min at 10 °C; the supernatant (plasma
~3 mL) is split into two vials (1.5 mL each) and
further centrifuged at 16,000 g for 10 min at
10 °C. Finally, plasma is transferred into two
1.5 mL tubes and stored at -80 °C
 Plasma (for proteomics and metabolomics studies): a
50 % solution of 3 mL of blood in protease inhibitor
is transferred in an EDTA-coated tube, centrifuged
at 1300 g for 10 min at 10 °C; the supernatant
(plasma ~1.5 mL) is split into three vials (0.5 mL
each) and stored at -80 °C.
Control groups
The criteria for the collection of the blood samples in the
patients will also be applied to the comparison groups of
septic patients and AMI or arrhythmic patients not in
shock. Regarding the blood donors, only one sample will
be taken and utilized as a healthy control benchmark for
the samples from the patients enrolled in the study.
Hemorrhagic shock
A critical element of the clinical protocol is the inclusion
of HS patients in the study. ShockOmics is aimed at in-
vestigating septic, cardiogenic and hemorrhagic shock in
human patients, and in swine shock models. However,
the –omics analyses impose extremely restrictive con-
straints on transfusions of blood and plasma, due to the
impossibility of disentangling the confounding factors
introduced by the donor blood. For these reasons, it has
not been deemed possible to perform the multiscale
investigation described for CS and SS in the case of
HS patients. The same multiscale approach, aimed at
combining –omics experiments with the mathematical
analysis of hemodynamic recordings, will be followed
in all the three (hemorrhagic, cardiogenic, septic)
swine models of shock.
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Still, for the sake of consistency with the general
framework of the project, a limited number of severe
hemorrhagic shock patients will be included in the data-
base, but only the hemodynamic signals will be collected
in these patients, without any blood samples and related
analysis.
Trial status
At the time of publication, 64 patients out of the
planned 90 have been recruited, and 12 controls out of
20. The study is expected to be completed by the first
quarter of 2016.
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